ZN-c3-005: Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer
Condition: Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Sponsor: K-Group, Beta, Inc.
Protocol ZN-c3-005: A Phase 2 Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zn‑c3 in Subjects With High-grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
WEE1 inhibitor ZN-c3 (azenosertib)
Indication: CCNE1 amplified high-grade serous Ovarian Carcinoma, Primary Peritoneal Carcinoma and Fallopian Tube Carcinoma
Line of therapy: Second line systemic treatment up to 3 lines with 1 line of platinum-based and bevacizumab therapies
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.